Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.52 |
| ▸ | PRKCA | P17252 | 5/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | GJB2 | P29033 | 1/20 | 0.47 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198642 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL8144862 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL8145211 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL4856848 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL5425896 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL6290144 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL3875391 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL2198649 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL10325897 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 | |
| SCHEMBL10326063 | 1.00 | TLR4 (0.52) | TLR4PRKCAAKT1MAPK1GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0454772-B1 | BLEACHING DETERGENT COMPOSITION | NOVO NORDISK AS (DK) | 1994-06-15 | — | — | EP | claimed |
| US-9951089-B2 | Methods of treating a fatty acid amide hydrolase-mediated condition | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-9034849-B2 | Fatty acid amide hydrolase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | INFINITY PHARMACEUTICALS, INC. | 2011-08-18 | — | — | US | disclosed |
| US-20100330596-A1 | LIPOPROTEIN SURFACTANT | ROCHE DIABETES CARE, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2164982-A2 | LIPOPROTEIN SURFACTANT | F.HOFFMANN-LA ROCHE AG (CH) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008152380-A2 | LIPOPROTEIN SURFACTANT | OXFORD BIOSENSORS LIMITED (GB) | 2008-12-18 | — | — | WO | disclosed |
| US-5431849-A | BIODEGRADABLE | NOVO NORDISK A/S (DK) | 1995-07-11 | — | — | US | disclosed |
| EP-0454772-B1 | BLEACHING DETERGENT COMPOSITION | NOVO NORDISK AS (DK) | 1994-06-15 | — | — | EP | disclosed |
| EP-0380437-A2 | Bleaching detergent composition | NOVO NORDISK A/S (DK) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201574-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | TLR4 4403/4885PRKCA 2261/4885AKT1 3468/4885 |
| US-20150239912-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS | FAAH, FAAH2, FASN | TLR4 4403/4885PRKCA 2261/4885AKT1 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.